Physician profile
Sujata Yavagal
NPI 1962499426
$7,195.11
in general payments reported to CMS, 2019-2025
21 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 81% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,694 · 2020: $175 · 2021: $969 · 2022: $427 · 2023: $812 · 2024: $358 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763 · Travel and Lodging: $982 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.29 |
| Travel and Lodging | $981.97 |
| Education | $184.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $1,541.37 | 2019 | |
| Medtronic, INC. | $1,307.89 | 2022-2025 | Interstim, Altaviva |
| Coloplast Corp | $910.10 | 2019-2025 | Altis |
| Axonics, INC. | $836.12 | 2021-2023 | Axonics |
| Astellas Pharma US INC | $564.27 | 2020-2025 | Veozah, Myrbetriq |
| Mission Pharmacal Company | $336.77 | 2019-2024 | Uribel, Uribel Tabs |
| Femselect INC. | $288.42 | 2024-2025 | Enplace |
| Abbvie INC. | $287.78 | 2019-2025 | Botox |
| Sumitomo Pharma America, INC. | $276.34 | 2023-2025 | Gemtesa |
| Pfizer INC. | $177.01 | 2019-2024 | |
| Allergan, INC. | $151.53 | 2019-2021 | |
| Urovant Sciences INC | $145.50 | 2021-2022 | |
| Millicent US INC | $105.44 | 2020-2025 | Intrarosa |
| Amag Pharmaceuticals, INC. | $66.39 | 2019-2020 | |
| Ge Healthcare | $56.54 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $33.71 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $28.89 | 2023 | |
| Lupin INC. | $26.09 | 2019-2021 | |
| Boston Scientific Corporation | $22.65 | 2025 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $18.09 | 2019 | |
| Laborie Medical Technologies Corp. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujata Yavagal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.